61 related articles for article (PubMed ID: 17685739)
1. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study.
Libov I; Miodownik C; Bersudsky Y; Dwolatzky T; Lerner V
J Clin Psychiatry; 2007 Jul; 68(7):1031-7. PubMed ID: 17685739
[TBL] [Abstract][Full Text] [Related]
2. Psychotropic Medications-Induced Tardive Dyskinesia and Associated Factors Among Patients with Mental Illness in Ethiopia.
Kumsa A; Girma S; Alemu B; Agenagnew L
Clin Pharmacol; 2020; 12():179-187. PubMed ID: 33293875
[TBL] [Abstract][Full Text] [Related]
3. The neuroprotective effects of Piracetam on cisplatin-induced cognitive decline.
Elbeltagy M; Khraisat B; AlZoubi L; Hmoud L; AlJeady A; Yousef M; Salman A
Int J Neurosci; 2023 Dec; ():1-8. PubMed ID: 38153438
[TBL] [Abstract][Full Text] [Related]
4. Correction: Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States.
Jain R; Ayyagari R; Goldschmidt D; Zhou M; Finkbeiner S; Leo S
J Patient Rep Outcomes; 2024 May; 8(1):51. PubMed ID: 38758345
[No Abstract] [Full Text] [Related]
5. Amoxapine-induced tardive dyskinesia.
Singh GP
Indian J Psychiatry; 2009; 51(4):327. PubMed ID: 20048464
[No Abstract] [Full Text] [Related]
6. Neurological perspectives should be integrated into the management of tardive dyskinesia - expert opinion and proposed educational initiatives in Asia.
Bhidayasiri R; Phokaewvarangkul O; Lim TT; Pal PK; Watanabe H; Cho JW; Shang HF
J Mov Disord; 2024 Apr; ():. PubMed ID: 38600683
[No Abstract] [Full Text] [Related]
7. Spotlight on respiratory dyskinesia: Recognizing an overlooked condition.
Solomon HV
Psychiatry Res; 2024 Jul; 337():115918. PubMed ID: 38692225
[No Abstract] [Full Text] [Related]
8. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.
Malykh AG; Sadaie MR
Drugs; 2010 Feb; 70(3):287-312. PubMed ID: 20166767
[TBL] [Abstract][Full Text] [Related]
9. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.
Lerner V; Miodownik C; Kaptsan A; Bersudsky Y; Libov I; Sela BA; Witztum E
J Clin Psychiatry; 2007 Nov; 68(11):1648-54. PubMed ID: 18052557
[TBL] [Abstract][Full Text] [Related]
10. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial.
Zhang WF; Tan YL; Zhang XY; Chan RC; Wu HR; Zhou DF
J Clin Psychiatry; 2011 May; 72(5):615-21. PubMed ID: 20868638
[TBL] [Abstract][Full Text] [Related]
11. The diffusion of performance and image-enhancing drugs (PIEDs) on the internet: the abuse of the cognitive enhancer piracetam.
Corazza O; Bersani FS; Brunoro R; Valeriani G; Martinotti G; Schifano F
Subst Use Misuse; 2014 Dec; 49(14):1849-56. PubMed ID: 24827869
[TBL] [Abstract][Full Text] [Related]
12. Cerebroprotective effect of piracetam in patients undergoing open heart surgery.
Holinski S; Claus B; Alaaraj N; Dohmen PM; Neumann K; Uebelhack R; Konertz W
Ann Thorac Cardiovasc Surg; 2011; 17(2):137-42. PubMed ID: 21597409
[TBL] [Abstract][Full Text] [Related]
13. Piracetam and other structurally related nootropics.
Gouliaev AH; Senning A
Brain Res Brain Res Rev; 1994 May; 19(2):180-222. PubMed ID: 8061686
[TBL] [Abstract][Full Text] [Related]
14. A double blind investigation of piracetam (Nootropil) vs placebo in geriatric memory.
Abuzzahab FS; Merwin GE; Zimmermann RL; Sherman MC
Pharmakopsychiatr Neuropsychopharmakol; 1977 Mar; 10(2):49-56. PubMed ID: 360232
[TBL] [Abstract][Full Text] [Related]
15. Study of the protective effects of nootropic agents against neuronal damage induced by amyloid-beta (fragment 25-35) in cultured hippocampal neurons.
Sendrowski K; Sobaniec W; Stasiak-Barmuta A; Sobaniec P; Popko J
Pharmacol Rep; 2015 Apr; 67(2):326-31. PubMed ID: 25712658
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the therapeutic efficacy of intravenous dimenhydrinate and intravenous piracetam in patients with vertigo: a randomised clinical trial.
Doğan NÖ; Avcu N; Yaka E; Yılmaz S; Pekdemir M
Emerg Med J; 2015 Jul; 32(7):520-4. PubMed ID: 25052217
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
Steg PG; Bhatt DL; Simon T; Fox K; Mehta SR; Harrington RA; Held C; Andersson M; Himmelmann A; Ridderstråle W; Leonsson-Zachrisson M; Liu Y; Opolski G; Zateyshchikov D; Ge J; Nicolau JC; Corbalán R; Cornel JH; Widimský P; Leiter LA;
N Engl J Med; 2019 Oct; 381(14):1309-1320. PubMed ID: 31475798
[TBL] [Abstract][Full Text] [Related]
18. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Pfeffer MA; Claggett B; Diaz R; Dickstein K; Gerstein HC; Køber LV; Lawson FC; Ping L; Wei X; Lewis EF; Maggioni AP; McMurray JJ; Probstfield JL; Riddle MC; Solomon SD; Tardif JC;
N Engl J Med; 2015 Dec; 373(23):2247-57. PubMed ID: 26630143
[TBL] [Abstract][Full Text] [Related]
19. Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation.
Kreinin A; Miodownik C; Sokolik S; Shestakova D; Libov I; Bergman J; Lerner V
World J Biol Psychiatry; 2011 Dec; 12(8):620-6. PubMed ID: 20964499
[TBL] [Abstract][Full Text] [Related]
20. Clozapine in tardive dyskinesia: observations from human and animal model studies.
Tamminga CA; Thaker GK; Moran M; Kakigi T; Gao XM
J Clin Psychiatry; 1994 Sep; 55 Suppl B():102-6. PubMed ID: 7961550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
